Thierry Brue

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1668666/thierry-brue-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264 papers	11,181 citations	59 h-index	97 g-index
357 ext. papers	12,959 ext. citations	4.2 avg, IF	5.75 L-index

#	Paper	IF	Citations
264	Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.. *Pituitary*, **2022**, 1	4.3	0
263	Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism.. *Endocrine*, **2022**, 76, 179	4	0
262	Current and Emerging Medical Therapies in Pituitary Tumors.. *Journal of Clinical Medicine*, **2022**, 11,	5.1	3
261	Clinical, radiological, and molecular diagnosis of congenital pituitary diseases causing short stature. *Archives De Pediatrie*, **2022**, 28, 28/8S33-28/8S38	1.8	
260	Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles?. *Frontiers in Endocrinology*, **2022**, 13, 832361	5.7	
259	Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).. *Orphanet Journal of Rare Diseases*, **2022**, 17, 178	4.2	0
258	Cost-Utility of Acromegaly Pharmacological Treatments in a French Context. *Frontiers in Endocrinology*, **2021**, 12, 745843	5.7	1
257	Fully endoscopic endonasal approach for the treatment of intrasellar arachnoid cysts. *Pituitary*, **2021**, 1	4.3	1
256	Lack of delayed neurocognitive side effects of Gamma Knife radiosurgery in acromegaly: the Later-Ac study. *European Journal of Endocrinology*, **2021**, 186, 37-44	6.5	1
255	Pre-term birth in women exposed to Cushing's disease: the baby-cush study. *European Journal of Endocrinology*, **2021**, 184, 469-476	6.5	2
254	Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. *European Journal of Endocrinology*, **2021**, 184, P1-P16	6.5	6
253	Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome. *Neurochirurgie*, **2021**, 67, 556-563	1.4	0
252	Osilodrostat in Cushing's disease: The risk of delayed adrenal insufficiency should be carefully monitored. *Clinical Endocrinology*, **2021**,	3.4	2
251	Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. *Endocrine*, **2021**, 71, 158-167	4	4
250	Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives. *Annales DŒndocrinologie*, **2021**, 82, 52-58	1.7	2
249	Women's perceptions of femininity after craniopharyngioma: a qualitative study. *Clinical Endocrinology*, **2021**, 94, 880-887	3.4	0
248	Clinical lessons learned in constitutional hypopituitarism from two decades of experience in a large international cohort. *Clinical Endocrinology*, **2021**, 94, 277-289	3.4	8

247	Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. *Pituitary*, **2021**, 24, 351-358	4.3	2
246	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. *Journal of the Endocrine Society*, **2021**, 5, bvaa205	0.4	14
245	The risks of medical treatment of prolactinoma. *Annales D'Endocrinologie*, **2021**, 82, 15-19	1.7	8
244	Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients). *Annales D'Endocrinologie*, **2021**, 82, 582-589	1.7	2
243	High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants underlying pituitary hormone deficiency. *American Journal of Human Genetics*, **2021**, 108, 1526-1539	11	5
242	Acromegaly in remission: a view from the partner. *European Journal of Endocrinology*, **2021**, 185, K21-K25	6.5	
241	Aggressive pituitary tumours and pituitary carcinomas. *Nature Reviews Endocrinology*, **2021**, 17, 671-684	15.2	15
240	More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. *European Journal of Endocrinology*, **2021**, 185, 525-538	6.5	7
239	Novel mechanism of pituitary hormone deficiency: genetic variants shift splicing to produce a dominant negative transcription factor isoform. *European Journal of Endocrinology*, **2021**, 185, C19-C25	6.5	1
238	Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma. *European Journal of Endocrinology*, **2021**, 184, 1-8	6.5	3
237	MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study. *Journal of the Endocrine Society*, **2020**, 4,	0.4	3
236	MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. *Endocrine*, **2020**, 69, 496-503	4	9
235	Hypopituitarism in Patients with Blepharophimosis and FOXL2 Mutations. *Hormone Research in Paediatrics*, **2020**, 93, 30-39	3.3	3
234	Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database. *Endocrine*, **2020**, 70, 134-142	4	2
233	Parasellar Meningiomas. *Neuroendocrinology*, **2020**, 110, 780-796	5.6	5
232	Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	11
231	Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: A multicentre study of 77 adult patients. *Clinical Endocrinology*, **2020**, 93, 248-260	3.4	4
230	Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. *Endocrine Connections*, **2020**, 9, 1178-1190	3.5	9

229	Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. *European Journal of Endocrinology*, **2020**, 182, 583	6.5	15
228	Germinal defects of SDHx genes in patients with isolated pituitary adenoma. *European Journal of Endocrinology*, **2020**, 183, 369-379	6.5	4
227	Evaluation of an individualized education program in pituitary diseases: a pilot study. *European Journal of Endocrinology*, **2020**, 183, 551-559	6.5	2
226	SAT-291 SIX3 Is Essential for Hypothalamic and Pituitary Development. *Journal of the Endocrine Society*, **2020**, 4,	0.4	1
225	Transcranial approach in giant pituitary adenomas: results and outcome in a modern series. *Journal of Neurosurgical Sciences*, **2020**, 64, 25-36	1.3	5
224	Adrenal Crisis May Occur Even In Patients With Asymptomatic Covid-19. *Endocrine Practice*, **2020**, 26, 929-930	3.2	1
223	Surgical indications for pituitary tumors during pregnancy: a literature review. *Pituitary*, **2020**, 23, 189-199	4.3	6
222	Fluctuation analysis of postoperative secretory status in patients operated for acromegaly. *Annales DŒEndocrinologie*, **2020**, 81, 11-17	1.7	0
221	Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient. *Annales DŒEndocrinologie*, **2020**, 81, 39-43	1.7	1
220	ESE audit on management of Adult Growth Hormone Deficiency in clinical practice. *European Journal of Endocrinology*, **2020**,	6.5	7
219	Genetic analysis of adult Slovenian patients with combined pituitary hormone deficiency. *Endocrine*, **2019**, 65, 379-385	4	2
218	LARGE ADRENAL INCIDENTALOMAS REQUIRE A DEDICATED DIAGNOSTIC PROCEDURE. *Endocrine Practice*, **2019**, 25, 669-677	3.2	5
217	Functioning gonadotroph adenoma with severe ovarian hyperstimulation syndrome: A new emergency in pituitary adenoma surgery? Surgical considerations and literature review. *Annales DŒEndocrinologie*, **2019**, 80, 122-127	1.7	8
216	Clinical management of difficult to treat macroprolactinomas. *Expert Review of Endocrinology and Metabolism*, **2019**, 14, 179-192	4.1	4
215	Acromegaly in Carney complex. *Pituitary*, **2019**, 22, 456-466	4.3	10
214	Letter to the Editor: "Why We Should Still Treat by Neurosurgery Patients With Cushing Disease and a Normal or Inconclusive Pituitary MRI". *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 5791-5792	5.6	3
213	SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant. *Journal of the Endocrine Society*, **2019**, 3,	0.4	2
212	X chromosome gene dosage as a determinant of congenital malformations and of age-related comorbidity risk in patients with Turner syndrome, from childhood to early adulthood. *European Journal of Endocrinology*, **2019**, 180, 397-406	6.5	9

211	Radiotherapy as a tool for the treatment of Cushing's disease. *European Journal of Endocrinology*, **2019**, 180, D9-D18	6.5	11
210	DIAGNOSIS OF ENDOCRINE DISEASE: Pituitary stalk interruption syndrome: etiology and clinical manifestations. *European Journal of Endocrinology*, **2019**, 181, R199-R209	6.5	19
209	MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis. *European Journal of Endocrinology*, **2019**, 181, R107-R118	6.5	42
208	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. *European Journal of Endocrinology*, **2019**, 181, 461-472	6.5	23
207	Ophthalmoplegic complications in transsphenoidal pituitary surgery. *Journal of Neurosurgery*, **2019**, 1-9	3.2	1
206	Pituitary Radiotherapy **2019**, 289-293		
205	SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience. *Journal of the Endocrine Society*, **2019**, 3,	0.4	78
204	Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. *Endocrine*, **2019**, 63, 563-572	4	14
203	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 213-220	18.1	52
202	Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study. *Endocrine*, **2019**, 63, 120-129	4	29
201	Heterozygous LHX3 mutations may lead to a mild phenotype of combined pituitary hormone deficiency. *European Journal of Human Genetics*, **2019**, 27, 216-225	5.3	10
200	Hepatic safety of ketoconazole in Cushing's syndrome: results of a Compassionate Use Programme in France. *European Journal of Endocrinology*, **2018**, 178, 447-458	6.5	30
199	Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. *European Journal of Endocrinology*, **2018**, 178, 399-409	6.5	24
198	Characterization of adrenocortical tumors by F-FDG PET/CT: Does steroid hormone hypersecretion status modify the uptake pattern?. *Surgical Oncology*, **2018**, 27, 231-235	2.5	3
197	MANAGEMENT OF ENDOCRINE DISEASE: Management of Cushing's syndrome during pregnancy: solved and unsolved questions. *European Journal of Endocrinology*, **2018**, 178, R259-R266	6.5	46
196	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 17-26	18.1	75
195	Looking beyond the thyroid: advances in the understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms. *Endocrine-Related Cancer*, **2018**, 25, T15-T28	5.7	15
194	Quantitative F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 278-282	8.8	20

193	Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults. *European Journal of Endocrinology*, **2018**, 179, 169-179	6.5	9
192	Lack of functional remission in Cushing's syndrome. *Endocrine*, **2018**, 61, 518-525	4	6
191	Active cushing syndrome patients have increased ectopic fat deposition and bone marrow fat content compared to cured patients and healthy subjects: a pilot 1H-MRS study. *European Journal of Endocrinology*, **2018**, 179, 307-317	6.5	13
190	Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. *European Journal of Endocrinology*, **2018**, 179, 419-427	6.5	42
189	Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly. *Pituitary*, **2018**, 21, 615-623	4.3	12
188	Cushing Syndrome Is Associated With Subclinical LV Dysfunction and Increased Epicardial Adipose Tissue. *Journal of the American College of Cardiology*, **2018**, 72, 2276-2277	15.1	8
187	A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. *European Journal of Endocrinology*, **2018**, 179, 97-108	6.5	23
186	Genes important in the fetal development of the pituitary. *Current Opinion in Endocrine and Metabolic Research*, **2018**, 1, 9-12	1.7	1
185	A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues. *European Journal of Endocrinology*, **2017**, 176, 421-431	6.5	17
184	MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. *European Journal of Endocrinology*, **2017**, 176, 323-328	6.5	19
183	Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. *European Journal of Endocrinology*, **2017**, 176, 645-655	6.5	89
182	Lessons from monogenic causes of growth hormone deficiency. *Annales D'Endocrinologie*, **2017**, 78, 77-79	2.7	6
181	Gamma Knife radiosurgery for hypothalamic hamartoma preserves endocrine functions. *Epilepsia*, **2017**, 58 Suppl 2, 72-76	6.4	11
180	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. *European Journal of Endocrinology*, **2017**, 176, 613-624	6.5	27
179	Development of ACRODAT, a new software medical device to assess disease activity in patients with acromegaly. *Pituitary*, **2017**, 20, 692-701	4.3	31
178	Pituitary gland: Gamma Knife for Cushing disease - time for a reappraisal?. *Nature Reviews Endocrinology*, **2017**, 13, 628-629	15.2	2
177	Pilot Neonatal Screening Program for Central Congenital Hypothyroidism: Evidence of Significant Detection. *Hormone Research in Paediatrics*, **2017**, 88, 274-280	3.3	9
176	Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database. *Endocrine-Related Cancer*, **2017**, 24, 505-518	5.7	110

175	Increased Risk of Persistent Glucose Disorders After Control of Acromegaly. *Journal of the Endocrine Society*, **2017**, 1, 1531-1539	0.4	10
174	Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?. *Oncotarget*, **2017**, 8, 41044-41063	3.3	18
173	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. *Endocrine-Related Cancer*, **2016**, 23, 871-881	5.7	47
172	Long-term outcome of macroprolactinomas. *Annales D'Endocrinologie*, **2016**, 77, 641-648	1.7	3
171	In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells. *Endocrine-Related Cancer*, **2016**, 23, 509-19	5.7	6
170	Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism?. *Endocrine-Related Cancer*, **2016**, 23, R131-42	5.7	35
169	MANAGEMENT OF ENDOCRINE DISEASE: Outcome of adrenal sparing surgery in heritable pheochromocytoma. *European Journal of Endocrinology*, **2016**, 174, R9-18	6.5	42
168	Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome. *Human Reproduction*, **2016**, 31, 782-8	5.7	100
167	Cancerous leptomeningitis and familial congenital hypopituitarism. *Endocrine*, **2016**, 52, 231-5	4	3
166	Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. *Endocrine*, **2016**, 53, 210-9	4	48
165	The Cables1 Gene in Glucocorticoid Regulation of Pituitary Corticotrope Growth and Cushing Disease. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 513-22	5.6	36
164	Combined Pituitary Hormone Deficiency **2016**, 177-194		1
163	MECHANISMS IN ENDOCRINOLOGY: An update in the genetic aetiologies of combined pituitary hormone deficiency. *European Journal of Endocrinology*, **2016**, 174, R239-47	6.5	41
162	Prevalence of KISS1 Receptor mutations in a series of 603 patients with normosmic congenital hypogonadotrophic hypogonadism and characterization of novel mutations: a single-centre study. *Human Reproduction*, **2016**, 31, 1363-74	5.7	34
161	GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency. *Hormone and Metabolic Research*, **2016**, 48, 389-93	3.1	17
160	Successful IVF pregnancy despite inadequate ovarian steroidogenesis due to congenital lipoid adrenal hyperplasia (CLAH): a case report. *Human Reproduction*, **2016**, 31, 2609-2612	5.7	15
159	The risks of overlooking the diagnosis of secreting pituitary adenomas. *Orphanet Journal of Rare Diseases*, **2016**, 11, 135	4.2	30
158	Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. *European Journal of Endocrinology*, **2015**, 172, R227-39	6.5	89

157	Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. *Endocrine-Related Cancer*, **2015**, 22, 169-77	5.7	56
156	Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. *Endocrine-Related Cancer*, **2015**, 22, 745-57	5.7	119
155	Clinical Outcome, Hormonal Status, Gonadotrope Axis, and Testicular Function in 219 Adult Men Born With Classic 21-Hydroxylase Deficiency. A French National Survey. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 2303-13	5.6	63
154	ISL1 Is Necessary for Maximal Thyrotrope Response to Hypothyroidism. *Molecular Endocrinology*, **2015**, 29, 1510-21		12
153	Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. *European Journal of Endocrinology*, **2015**, 172, 195-204	6.5	171
152	Combined pituitary hormone deficiency: current and future status. *Journal of Endocrinological Investigation*, **2015**, 38, 1-12	5.2	30
151	Successful pregnancies and healthy live births using frozen-thawed sperm retrieved by a new modified Hotchkiss procedure in males with retrograde ejaculation: first case series. *Basic and Clinical Andrology*, **2015**, 25, 5	2.8	12
150	Postoperative follow-up of Cushing's disease using cortisol, desmopressin and coupled dexamethasone-desmopressin tests: a head-to-head comparison. *Clinical Endocrinology*, **2015**, 83, 216-22	3.4	14
149	Dose-dependent dual role of PIT-1 (POU1F1) in somatolactotroph cell proliferation and apoptosis. *PLoS ONE*, **2015**, 10, e0120010	3.7	2
148	Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY. *Annales D'Endocrinologie*, **2015**, 76, 664-70	1.7	19
147	An observational study on adrenal insufficiency in a French tertiary centre: Real life versus theory. *Annales D'Endocrinologie*, **2015**, 76, 1-8	1.7	8
146	Identifying the Deleterious Effect of Rare LHX4 Allelic Variants, a Challenging Issue. *PLoS ONE*, **2015**, 10, e0126648	3.7	14
145	Ketoconazole in Cushing's disease: is it worth a try?. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 1623-30	5.6	188
144	Evidence for an internal and functional circadian clock in rat pituitary cells. *Molecular and Cellular Endocrinology*, **2014**, 382, 888-98	4.4	13
143	Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. *Endocrine-Related Cancer*, **2014**, 21, 691-704	5.7	39
142	A monocentric experience of growth hormone replacement therapy in adult patients. *Annales D'Endocrinologie*, **2014**, 75, 176-83	1.7	7
141	Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 875-84	18.1	233
140	Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. *Lancet Oncology, The*, **2014**, 15, 648-55	21.7	110

139	Mutations in NFKB2 and potential genetic heterogeneity in patients with DAVID syndrome, having variable endocrine and immune deficiencies. *BMC Medical Genetics*, **2014**, 15, 139	2.1	56
138	Ghrelin receptor (GHS-R1a) and its constitutive activity in somatotroph adenomas: a new co-targeting therapy using GHS-R1a inverse agonists and somatostatin analogs. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E2463-71	5.6	4
137	Pituitary apoplexy after somatostatin analogue administration: coincidental or causative?. *Clinical Endocrinology*, **2014**, 81, 471-3	3.4	5
136	Bilateral neck exploration in patients with primary hyperparathyroidism and discordant imaging results: a single-centre study. *European Journal of Endocrinology*, **2014**, 170, 719-25	6.5	23
135	Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. *Diabetes and Metabolism*, **2013**, 39, 34-41	5.4	49
134	Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients. *Clinical Endocrinology*, **2013**, 78, 263-70	3.4	31
133	A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. *Acta Neuropathologica*, **2013**, 126, 123-35	14.3	276
132	Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. *European Journal of Endocrinology*, **2013**, 168, 533-41	6.5	110
131	Delayed diagnosis of Sheehan's syndrome in a developed country: a retrospective cohort study. *European Journal of Endocrinology*, **2013**, 169, 431-8	6.5	26
130	R31C GNRH1 mutation and congenital hypogonadotropic hypogonadism. *PLoS ONE*, **2013**, 8, e69616	3.7	12
129	Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. *Clinical Endocrinology*, **2012**, 76, 769-75	3.4	109
128	Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. *Annales DŒndocrinologie*, **2012**, 73, 225-9	1.7	21
127	The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling. *Genes and Development*, **2012**, 26, 2299-310	12.6	100
126	Cushing's disease. *Orphanet Journal of Rare Diseases*, **2012**, 7, 41	4.2	37
125	Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 1589-97	5.6	184
124	Genetic causes of combined pituitary hormone deficiencies in humans. *Annales DŒndocrinologie*, **2012**, 73, 53-5	1.7	15
123	Unilateral agenesis of internal carotid artery associated with congenital combined pituitary hormone deficiency and pituitary stalk interruption without HESX1, LHX4 or OTX2 mutation: a case report. *Pituitary*, **2012**, 15 Suppl 1, S81-6	4.3	8
122	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. *European Journal of Endocrinology*, **2012**, 167, 651-62	6.5	130

121	The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2012**, 19, 295-9	4	34
120	Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. *Endocrine-Related Cancer*, **2012**, 19, 233-41	5.7	61
119	Phenotypic homogeneity and genotypic variability in a large series of congenital isolated ACTH-deficiency patients with TPIT gene mutations. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E486-95	5.6	51
118	Deficit in anterior pituitary function and variable immune deficiency (DAVID) in children presenting with adrenocorticotropin deficiency and severe infections. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E121-8	5.6	37
117	PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E1068-73	5.6	60
116	Adrenal myelolipoma: an unusual cause of bilateral highly 18F-FDG-avid adrenal masses. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 2577-8	5.6	12
115	Inactivation of transcription factor pit-1 to target tumoral somatolactotroph cells. *Human Gene Therapy*, **2012**, 23, 104-14	4.8	8
114	Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. *QJM - Monthly Journal of the Association of Physicians*, **2012**, 105, 981-95	2.7	88
113	Ipilimumab-induced hypophysitis in melanoma patients.. *Journal of Clinical Oncology*, **2012**, 30, 8568-8568	2.2	1
112	Truncation of PITX2 differentially affects its activity on physiological targets. *Journal of Molecular Endocrinology*, **2011**, 46, 9-19	4.5	9
111	Inactivation of PITX2 transcription factor induced apoptosis of gonadotroph tumoral cells. *Endocrinology*, **2011**, 152, 3884-92	4.8	17
110	PITX2 AND PITX1 regulate thyrotroph function and response to hypothyroidism. *Molecular Endocrinology*, **2011**, 25, 1950-60		21
109	Clinical, biological and genetic analysis of 8 cases of congenital isolated adrenocorticotrophic hormone (ACTH) deficiency. *PLoS ONE*, **2011**, 6, e26516	3.7	7
108	Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. *European Journal of Endocrinology*, **2011**, 164, 877-84	6.5	113
107	Detection of genetic hypopituitarism in an adult population of idiopathic pituitary insufficiency patients with growth hormone deficiency. *Pituitary*, **2011**, 14, 208-16	4.3	11
106	Case seminar: a young female with acute hyponatremia and a sellar mass. *Endocrine*, **2011**, 40, 325-31	4	12
105	Pituitary stem cell update and potential implications for treating hypopituitarism. *Endocrine Reviews*, **2011**, 32, 453-71	27.2	76
104	Lessons learned from 15 years of KIMS and 5 years of ACROSTUDY. *Hormone Research in Paediatrics* , **2011**, 76 Suppl 1, 33-8	3.3	14

103	Pituitary stalk interruption syndrome in 83 patients: novel HESX1 mutation and severe hormonal prognosis in malformative forms. *European Journal of Endocrinology*, **2011**, 164, 457-65	6.5	62
102	High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. *European Journal of Endocrinology*, **2011**, 165, 509-15	6.5	124
101	A conservative management is preferable in milder forms of pituitary tumor apoplexy. *Journal of Endocrinological Investigation*, **2011**, 34, 502-9	5.2	16
100	Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, E373-83	5.6	259
99	Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 4680-7	5.6	84
98	Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone. *Neuroendocrinology*, **2010**, 92 Suppl 1, 125-30	5.6	44
97	Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 1708-16	5.6	118
96	A comparative phenotypic study of kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 659-69	5.6	103
95	Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis. *Molecular Endocrinology*, **2010**, 24, 1835-45		59
94	Familial pituitary adenomas. *Annales D'Endocrinologie*, **2010**, 71, 479-85	1.7	10
93	Adenomi ipofisari. *EMC - AKOS - Trattato Di Medicina*, **2010**, 12, 1-12	0	
92	Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. *Clinical Pharmacokinetics*, **2010**, 49, 455-63	6.2	41
91	Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 4592-9	5.6	178
90	Comparative validation of the growth hormone-releasing hormone and arginine test for the diagnosis of adult growth hormone deficiency using a growth hormone assay conforming to recent international recommendations. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 3684-92	5.6	19
89	Molecular mechanisms of pituitary organogenesis: In search of novel regulatory genes. *Molecular and Cellular Endocrinology*, **2010**, 323, 4-19	4.4	122
88	Adenomas hipofisarios. *EMC - Tratado De Medicina*, **2010**, 14, 1-12	0	
87	Role of stereotactic radiosurgery in the management of pituitary adenomas. *Nature Reviews Endocrinology*, **2010**, 6, 214-23	15.2	82
86	Adénomes hypophysaires. *EMC - Traité De Médecine AKOS*, **2010**, 5, 1-12		

85	Gamma Knife radiosurgery in pituitary adenomas: Why, who, and how to treat?. *Discovery Medicine*, **2010**, 10, 107-11	2.5	6
84	Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 3400-7	5.6	137
83	Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. *European Journal of Endocrinology*, **2009**, 161 Suppl 1, S11-7	6.5	14
82	A combined dexamethasone desmopressin test as an early marker of postsurgical recurrence in Cushing's disease. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 1897-903	5.6	36
81	Merits and pitfalls of mifepristone in Cushing's syndrome. *European Journal of Endocrinology*, **2009**, 160, 1003-10	6.5	113
80	ACROSTUDY: Status Update on 469 Patients. *Hormone Research in Paediatrics*, **2009**, 71 Suppl 1, 34-8	3.3	16
79	Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. *Endocrine-Related Cancer*, **2009**, 16, 1029-43	5.7	115
78	Radiotherapy and radiosurgery in acromegaly. *Pituitary*, **2009**, 12, 3-10	4.3	45
77	Lanreotide for the treatment of acromegaly. *Advances in Therapy*, **2009**, 26, 600-12	4.1	14
76	French consensus on the management of acromegaly. *Annales DŒEndocrinologie*, **2009**, 70, 92-106	1.7	18
75	La chirurgie de premi□e intention a-t-elle encore une place dans le traitement de l□acrom□galie ?. *Annales DŒEndocrinologie*, **2009**, 70, e23-e28	1.7	
74	Consensus fran□ais sur la prise en charge de l□acrom□galie. *Annales DŒEndocrinologie*, **2009**, 70, e9-e22	1.7	3
73	Does first-line surgery still have its place in the treatment of acromegaly?. *Annales DŒEndocrinologie*, **2009**, 70, 107-12	1.7	12
72	Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. *Molecular and Cellular Endocrinology*, **2008**, 286, 206-13	4.4	38
71	Congenital pituitary hormone deficiencies: role of LHX3/LHX4 genes. *Expert Review of Endocrinology and Metabolism*, **2008**, 3, 751-760	4.1	1
70	Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. *Cancer Research*, **2008**, 68, 10163-70	10.1	39
69	Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. *European Journal of Endocrinology*, **2008**, 158, 91-9	6.5	127
68	A novel dysfunctional LHX4 mutation with high phenotypical variability in patients with hypopituitarism. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 2790-9	5.6	65

67	Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1891-6	5.6	243
66	Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. *European Journal of Endocrinology*, **2007**, 156, 91-8	6.5	145
65	Chirurgie des prolactinomes. *Annales D'Endocrinologie*, **2007**, 68, e35-e36	1.7	
64	Diagnosis and management of hyperprolactinemia: expert consensus - French Society of Endocrinology. *Annales D'Endocrinologie*, **2007**, 68, 58-64	1.7	27
63	Prolactinoma surgery. *Annales D'Endocrinologie*, **2007**, 68, 118-9	1.7	12
62	Diagnostic étiologique d'une hyperprolactinémie. *Annales D'Endocrinologie*, **2007**, 68, e15-e22	1.7	
61	Diagnostic et prise en charge des hyperprolactinémies : Consensus d'experts de la Société française d'endocrinologie (SFE). *Annales D'Endocrinologie*, **2007**, 68, e8-e14	1.7	2
60	Etiological diagnosis of hyperprolactinemia. *Annales D'Endocrinologie*, **2007**, 68, 98-105	1.7	18
59	Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. *International Journal of Cancer*, **2007**, 121, 1245-52	7.5	30
58	Gamma knife surgery for epilepsy related to hypothalamic hamartomas. *Seminars in Pediatric Neurology*, **2007**, 14, 73-9	2.9	85
57	Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1952-5	5.6	112
56	Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH-dependent Cushing's syndrome. *European Journal of Endocrinology*, **2007**, 157, 271-7	6.5	61
55	Activin inhibits the human Pit-1 gene promoter through the p38 kinase pathway in a Smad-independent manner. *Endocrinology*, **2006**, 147, 4351-62	4.8	28
54	The role of CBP/p300 interactions and Pit-1 dimerization in the pathophysiological mechanism of combined pituitary hormone deficiency. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 239-47	5.6	23
53	Identification and functional analysis of the novel S179R POU1F1 mutation associated with combined pituitary hormone deficiency. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 4981-7	5.6	20
52	Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. *Genes and Development*, **2006**, 20, 2871-86	12.6	176
51	Genetic screening of combined pituitary hormone deficiency: experience in 195 patients. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 3329-36	5.6	111
50	Clinical characterization of familial isolated pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 3316-23	5.6	182

49	Insuffisance ante hypophysaire post-radique. *Annales D'Endocrinologie*, **2006**, 67, e10-e17	1.7	
48	Pituitary deficiency after brain radiation therapy. *Annales D'Endocrinologie*, **2006**, 67, 303-9	1.7	10
47	Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. *Clinical Endocrinology*, **2006**, 65, 265-73	3.4	558
46	Pituitary transcription factors: from congenital deficiencies to gene therapy. *Journal of Neuroendocrinology*, **2006**, 18, 633-42	3.8	53
45	Epilepsy related to hypothalamic hamartomas: surgical management with special reference to gamma knife surgery. *Child's Nervous System*, **2006**, 22, 881-95	1.7	127
44	Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 1323-31	5.6	105
43	Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 4483-8	5.6	188
42	Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 4762-70	5.6	94
41	An uncommon phenotype with familial central hypogonadism caused by a novel PROP1 gene mutant truncated in the transactivation domain. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 4880-7	5.6	54
40	A familial form of congenital hypopituitarism due to a PROP1 mutation in a large kindred: phenotypic and in vitro functional studies. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 5779-86	5.6	59
39	The desmopressin test as a predictive factor of outcome after pituitary surgery for Cushing's disease. *European Journal of Endocrinology*, **2004**, 151, 727-33	6.5	33
38	A neonatal form of isolated ACTH deficiency frequently associated with Tpit gene mutations. *Endocrine Research*, **2004**, 30, 943-4	1.9	6
37	Gamma knife surgery for epilepsy related to hypothalamic hamartomas. *Acta Neurochirurgica Supplementum*, **2004**, 91, 33-50	1.7	52
36	Pituitary hormone deficiencies due to transcription factor gene alterations. *Growth Hormone and IGF Research*, **2004**, 14, 442-8	2	24
35	Differential regulation of proopiomelanocortin and pituitary-restricted transcription factor (TPIT), a new marker of normal and adenomatous human corticotrophs. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 3050-6	5.6	46
34	Human and mouse TPIT gene mutations cause early onset pituitary ACTH deficiency. *Genes and Development*, **2003**, 17, 711-6	12.6	157
33	Macroprolactinemia revisited: a study on 106 patients. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 581-8	5.6	176
32	Author's Response: Macroprolactinemia Revisited—A Study on 106 Patients. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 4834-4834	5.6	1

31	Pseudotumor of the pituitary due to PROP-1 deletion. *Journal of Pediatric Endocrinology and Metabolism*, **2002**, 15, 95-101	1.6	14
30	PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 4529-35	5.6	97
29	Combined pituitary hormone deficiency due to the F135C human Pit-1 (pituitary-specific factor 1) gene mutation: functional and structural correlates. *Molecular Endocrinology*, **2001**, 15, 411-20		23
28	A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. *Cell*, **2001**, 104, 849-59	56.2	431
27	Tpit, un nouveau membre de la famille des gnes boe T, est impliqu dans la dficience isole en ACTH. *Medecine/Sciences*, **2001**, 17, 1203-1207		
26	Markers of tumor invasion are major predictive factors for the long-term outcome of corticotroph microadenomas treated by transsphenoidal adenomectomy. *European Journal of Endocrinology*, **2000**, 143, 761-8	6.5	11
25	Defective retinoic acid regulation of the Pit-1 gene enhancer: a novel mechanism of combined pituitary hormone deficiency. *Molecular Endocrinology*, **1999**, 13, 476-84		60
24	An ultrarapid prognostic index in microprolactinoma surgery. *Journal of Neurosurgery*, **1999**, 90, 1037-41	3.2	7
23	The hormonal response to stress is not modified by the dramatic decrease in prolactin plasma concentration during surgery for microprolactinoma. *Journal of Neurology, Neurosurgery and Psychiatry*, **1998**, 65, 502-7	5.5	3
22	Macroprolactinemia: a cause of hyperprolactinemia in childhood. *Journal of Pediatric Endocrinology and Metabolism*, **1997**, 10, 411-7	1.6	10
21	Insulin-induced lipoatrophy in type I diabetes. A possible tumor necrosis factor-alpha-mediated dedifferentiation of adipocytes. *Diabetes Care*, **1996**, 19, 1283-5	14.6	38
20	A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency. *Journal of Clinical Endocrinology and Metabolism*, **1996**, 81, 2790-6	5.6	51
19	Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. *European Journal of Endocrinology*, **1996**, 135, 413-20	6.5	85
18	A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency. *Journal of Clinical Endocrinology and Metabolism*, **1996**, 81, 2790-2796	5.6	61
17	Pattern of prolactin diurnal secretion in normal humans: evidence for nonlinear dynamics. *Neuroendocrinology*, **1995**, 62, 444-53	5.6	10
16	Glycosylated and non-glycosylated prolactin forms are increased after opioid administration as part of surgical anaesthesia. *Clinical Endocrinology*, **1995**, 43, 213-7	3.4	10
15	3-D-FT Thin-Section MRI of Prolactin-Secreting Microadenomas **1994**, 354-363		
14	3D-FT thin sections MRI of prolactin-secreting pituitary microadenomas. *Neuroradiology*, **1994**, 36, 376-9	3.2	7

13	Evaluation of three-dimensional MRI exploration of prolactin-secreting microadenomas. *Journal of Neuroradiology*, **1993**, 20, 213-25	3.1	2
12	Immunoradiometric analysis of circulating human glycosylated and nonglycosylated prolactin forms: spontaneous and stimulated secretions. *Journal of Clinical Endocrinology and Metabolism*, **1992**, 75, 1338-44	5.6	27
11	Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. *Journal of Clinical Endocrinology and Metabolism*, **1992**, 74, 577-84	5.6	55
10	Prolactin isoforms secreted by human prolactinomas. *Hormone Research*, **1992**, 38, 164-70		14
9	Prolactinomas and resistance to dopamine agonists. *Hormone Research*, **1992**, 38, 84-9		68
8	A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study. *Fertility and Sterility*, **1992**, 57, 74-80	4.8	3
7	Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. *Journal of Clinical Endocrinology and Metabolism*, **1992**, 74, 577-584	5.6	46
6	Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. *Journal of Clinical Endocrinology and Metabolism*, **1992**, 75, 540-546	5.6	58
5	Immunoradiometric analysis of circulating human glycosylated and nonglycosylated prolactin forms: spontaneous and stimulated secretions. *Journal of Clinical Endocrinology and Metabolism*, **1992**, 75, 1338-1344	5.6	19
4	Severe fibromyalgia after hypophysectomy for Cushing's disease. *Arthritis and Rheumatism*, **1991**, 34, 493-5		18
3	Enlarged adenomectomy for enclosed prolactinomas: a preliminary study of 26 cases. *Acta Neurochirurgica*, **1990**, 103, 92-8	3	10
2	Macroprolactinemia Revisited: A Study on 106 Patients		59
1	Predictors of response to long-acting pasireotide in patients with Cushing's disease during a Phase III study. *Endocrine Abstracts*,		2